The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly’s experimental medication olomorasib as a potential treatment for previously…
News
Most myeloma patients taking Tecvayli (teclistamab-cqyv) were alive and free from disease progression two years after starting treatment, according to a new analysis…
A large, late-stage clinical trial testing an immunotherapy in people with gynecological cancers is recruiting participants ahead of schedule, even amid the typically slower…
A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…
A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…
The experimental anticancer therapy CR-001 was generally well tolerated in a first-in-human clinical trial that tested several doses in 11 people with acute myeloid leukemia…
Maintenance therapy for myeloma can be stopped after two years without raising the risk of disease progression or death, a new study shows. “For…
An anticancer vaccine targeting a common genetic driver of pancreatic cancer was shown to be safe in an early clinical trial, with the results…
Dosing has begun in a Phase 3 clinical trial testing whether the antibody therapy Gamunex-C (immune globulin injection [human], 10% caprylate/chromatography purified) can help prevent…
Combining immunotherapy with an experimental cell therapy from Ernexa Therapeutics completely eliminated ovarian cancer in two-thirds of mice in laboratory experiments. The new data,…
